Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 83Squamous Cell Carcinoma of Head and Neck 51Carcinoma, Non-Small-Cell Lung 30Head and Neck Neoplasms 29Colonic Neoplasms 22Neoplasm Metastasis 18Neoplasms 16Rectal Neoplasms 14Pancreatic Neoplasms 10Lung Neoplasms 10Mouth Neoplasms 8Carcinoma, Squamous Cell 8Laryngeal Neoplasms 7Hypopharyngeal Neoplasms 7Oropharyngeal Neoplasms 6Carcinoma 6Solid Tumors 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Gastrointestinal Neoplasms 5Breast Neoplasms 5Tongue Neoplasms 4Ovarian Neoplasms 4Endometrial Neoplasms 4Thyroid Neoplasms 3Recurrence 3Melanoma 3Digestive System Neoplasms 3Colorectal Cancer Metastatic 3Carcinoma, Renal Cell 3Carcinoma, Pancreatic Ductal 3

Interventions

trifluridine tipiracil drug combination 1regorafenib 1defactinib 1Oxaliplatin 1HMPL-013 1Cetuximab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Colorectal Cancer × Cetuximab × 1 year × Clear all
NCT06369259 2026-05-20

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Recruiting
33 enrolled
Gastrointestinal

Advanced Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡